IL280014A - Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting CTLA-4 - Google Patents

Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting CTLA-4

Info

Publication number
IL280014A
IL280014A IL280014A IL28001421A IL280014A IL 280014 A IL280014 A IL 280014A IL 280014 A IL280014 A IL 280014A IL 28001421 A IL28001421 A IL 28001421A IL 280014 A IL280014 A IL 280014A
Authority
IL
Israel
Prior art keywords
ctla
engineered
compositions
antigen binding
binding domain
Prior art date
Application number
IL280014A
Other languages
English (en)
Hebrew (he)
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of IL280014A publication Critical patent/IL280014A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL280014A 2018-07-11 2021-01-07 Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting CTLA-4 IL280014A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696754P 2018-07-11 2018-07-11
US201862743976P 2018-10-10 2018-10-10
PCT/US2019/041293 WO2020014413A2 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4

Publications (1)

Publication Number Publication Date
IL280014A true IL280014A (en) 2021-03-01

Family

ID=69141692

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280014A IL280014A (en) 2018-07-11 2021-01-07 Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting CTLA-4

Country Status (11)

Country Link
US (1) US20220064298A1 (cg-RX-API-DMAC7.html)
EP (1) EP3820521A4 (cg-RX-API-DMAC7.html)
JP (1) JP2021532085A (cg-RX-API-DMAC7.html)
KR (1) KR20210044783A (cg-RX-API-DMAC7.html)
CN (1) CN113395978A (cg-RX-API-DMAC7.html)
AU (1) AU2019301160A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021000427A2 (cg-RX-API-DMAC7.html)
CA (1) CA3106207A1 (cg-RX-API-DMAC7.html)
IL (1) IL280014A (cg-RX-API-DMAC7.html)
MX (1) MX2021000306A (cg-RX-API-DMAC7.html)
WO (1) WO2020014413A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
TWI915400B (zh) * 2020-08-14 2026-02-21 日商中外製藥股份有限公司 單臂抗原結合分子及其用途
CN117157328A (zh) * 2021-01-28 2023-12-01 儿童医院 Multabody构建体、组合物和方法
IL308633B2 (en) * 2021-06-25 2025-12-01 Chugai Pharmaceutical Co Ltd Use of anti-ctla-4 antibody
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
WO2024212152A1 (en) * 2023-04-13 2024-10-17 Adagene Pte. Ltd. Anti-ctla4 antibodies and methods of making and using the same
EP4731655A1 (en) * 2023-06-23 2026-04-29 CureVac SE Nucleic acid encoded antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR075989A1 (es) * 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CA2994746A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
US12391759B2 (en) * 2016-03-02 2025-08-19 Momenta Pharmaceuticals, Inc. Methods related to engineered Fc constructs
IL309293A (en) * 2016-05-23 2024-02-01 Momenta Pharmaceuticals Inc Compositions and methods relating to engineered FC constructs
WO2018035710A1 (en) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JP6976322B2 (ja) * 2016-10-10 2021-12-08 クラウン バイオサイエンス,インコーポレイテッド(タイツァン) 新規抗ctla4抗体
EP3538551A4 (en) * 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. CD46 SPECIFIC EFFECTOR CELLS AND USES THEREOF
CN106913869B (zh) * 2017-03-17 2020-07-28 信达生物制药(苏州)有限公司 一种抗ctla-4单克隆抗体制剂及其应用

Also Published As

Publication number Publication date
EP3820521A4 (en) 2022-04-13
AU2019301160A1 (en) 2021-02-25
US20220064298A1 (en) 2022-03-03
WO2020014413A3 (en) 2020-02-20
JP2021532085A (ja) 2021-11-25
EP3820521A2 (en) 2021-05-19
MX2021000306A (es) 2021-09-08
CN113395978A (zh) 2021-09-14
BR112021000427A2 (pt) 2021-04-06
CA3106207A1 (en) 2020-01-16
WO2020014413A2 (en) 2020-01-16
KR20210044783A (ko) 2021-04-23

Similar Documents

Publication Publication Date Title
EP3565595A4 (en) COMPOSITIONS AND PROCEDURES RELATED TO MANIPULATED FC ANTIGEN BINDING DOMAIN CONSTRUCTS
IL279998A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL263211B1 (en) Compositions and methods relating to engineered fc constructs
IL280046A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeted to CD38
IL272103A (en) Antigen-binding proteins binding to 5T4 and 4-1BB, compositions and methods
SG11202001208XA (en) Rna targeting methods and compositions
IL247442B (en) Compositions and methods relating to engineered fc constructs
IL280044A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
HUE050279T2 (hu) Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei
SG11202102030RA (en) Novel nuclease domain and uses thereof
IL280038A (en) Compositions and methods relating to engineered constructs with an antigen-binding site FC targeting PD-L1
EP3820521A4 (en) COMPOSITIONS AND METHODS RELATED TO MANIPULATED FC ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
EP3820517A4 (en) COMPOSITIONS AND METHODS RELATED TO CCR4-TARGETED FC ANTIGEN-BINDING DOMAIN CONSTRUCTIONS
IL279999A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
IL279989A (en) Compositions and methods relating to engineered constructs with an antigen-binding site-FC
EP3618869A4 (en) COMPOSITIONS AND PROCEDURES RELATED TO XCT ANTIBODIES
HK40053034A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
HK40053035A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
IL291465A (en) Compositions and methods relating to engineered fc-antigen binding region constructs targeted to cd38
HK40053037A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
HK40053031A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053032A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053036A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053033A (en) Compositions and methods related to engineered fc-antigen binding domain constructs
HK40053238A (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4